TITLE

Visceral Leishmaniasis Simulating Chronic Liver Disease: Successful Treatment with Miltefosine

PUB. DATE
January 2009
SOURCE
Indian Journal of Medical Microbiology;Jan2009, Vol. 27 Issue 1, p85
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
36333558

 

Related Articles

  • Efficacy of miltefosine declined for visceral leishmaniasis in India.  // Infectious Disease News;Sep2012, Vol. 25 Issue 9, p34 

    The article reports on the increase in the failure rate of miltefosine for the treatment of visceral leishmaniasis in India.

  • Post-kala-azar Dermal Leishmaniasis Developing in Miltefosine-treated Visceral Leishmaniasis. Koley, Sankha; Kumar Mandal, Rajesh; Choudhary, Sanjiv; Bandyopadhyay, Arghya // Indian Journal of Dermatology;May/Jun2013, Vol. 58 Issue 3, p282 

    Post-kala-azar dermal leishmaniasis (PKDL) is an unusual dermatosis occurring following an attack of visceral leishmaniasis (VL). There are only few reports of PKDL after successful treatment with miltefosine. We report two cases of PKDL that developed after successful treatment of VL with...

  • Miltefosine.  // Reactions Weekly;Dec2014, Vol. 1531 Issue 1, p132 

    An abstract of the article "Fatal acute pancreatitis in a patient with visceral leishmaniasis during miltefosine treatment," by K. Pandey and colleagues is presented.

  • Building Research Capacity into Drug Development. Karbwang, J.; Ganguly, N. K. // Applied Clinical Trials;Sep2006, Vol. 15 Issue 9, p38 

    The article focuses on the agreement of the Special Programme for Research and Training (TDR) in Tropical Diseases to collaborate with pharmaceutical firm Asta Medica AG, to develop miltefosine for the treatment of visceral leishmaniasis in India. The compound was assessed and incorporated into...

  • Localised Leishmaniasis of Oral Mucosa: Report of an Unusual Clinicopathological Entity. Passi, Deepak; Sharma, Sarang; Dutta, Shubharanjan; Gupta, Chandan // Case Reports in Dentistry;2014, p1 

    The term leishmaniasis comprises of a group of diseases caused by different species of a protozoan called Leishmania. There are three main clinical forms of leishmaniasis: visceral leishmaniasis, cutaneous leishmaniasis, and mucocutaneous leishmaniasis. Exclusive involvement of the mucosa is...

  • The Treatment of Visceral Leishmaniasis: Safety and Effıcacy. Kumar Jha, Rajesh; Kumar Sah, Ajit; Kumar Shah, Dev; Sah, Phoolgen // Journal of the Nepal Medical Association;Oct-Dec2013, Vol. 52 Issue 192, p645 

    Visceral leishmaniasis is the disease of poor; however availability of only expensive treatment of this disease impinges the socioeconomic condition of those affected. If untreated, almost all cases of visceral leishmaniasis are fatal. The demonstration of the leishmania donovani bodies from the...

  • An Oral Drug for Leishmaniasis. Jacobs, Sandra // New England Journal of Medicine;11/28/2002, Vol. 347 Issue 22, p1737 

    Discusses the use of miltefosine for treatment of visceral leishmaniasis. Incidence of death from leishmaniasis in India; Development of this oral drug for use; Factors which led to the success of this study; Use of clinical monitors in the study; Reference to an article about the results of a...

  • Lingual Leishmaniasis Presenting to Maxillofacial Surgery in UK with Successful Treatment with Miltefosine. Kassam, K.; Davidson, R.; Tadrous, P. J.; Kumar, M. // Case Reports in Medicine;2013, p1 

    Leishmaniasis is a disease that is caused by protozoa of the genus Leishmania, which is prevalent in tropical and subtropical areas. Clinical forms of leishmaniasis are particularly diverse representing a complex of diseases. We present a case of lingual Leishmaniasis in an immunocompetent man....

  • Sodium Stibogluconate. Shrestha, Nabin K. // Clinical Infectious Diseases;11/15/2006, Vol. 43 Issue 10, p1371 

    A letter to the editor in response to an article by K. Ritmeijer and colleagues on the effectiveness of miltefosine and sodium stibogluconate in the treatment of visceral leishmaniasis published in a previous issue of this journal is presented.

  • CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis. Sane, Shraddha A.; Shakya, Nishi; Haq, W.; Gupta, Suman // Journal of Antimicrobial Chemotherapy (JAC);Jul2010, Vol. 65 Issue 7, p1448 

    Objectives: To evaluate the combination of CpG oligodeoxynucleotide (CpG ODN) and miltefosine for the treatment of experimental visceral leishmaniasis (VL).

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics